WHO to meet next week to consider emergency use listing of India's Covaxin

The WHOs technical advisory group will meet on October 26 to consider the emergency use listing of Indias Covaxin which is being used in the countrys nationwide antiCovid19 vaccination programme according to the global health agencys chief scientist Soumya SwaminathanHyderabadbased Bharat Biotech which has developed Covaxin had submitted EOI Expression of Interest to the World Health Organisation on April 19 for its vaccineSwaminathan the WHOs Chief Scientist said on Twitter on Sunday that the technical advisory group will meet on October 26 to consider the Emergency Use Listing EUL for CovaxinldquoWHO has been working closely with BharatBiotech to complete the dossier Our goal is to have a broad portfolio of vaccines approved for emergency use and to expand access to populations everywhere she said in the tweetAlso Read Covid19 Expert panel recommends emergency use approval for Covaxin in 2 to 18 age groupEarlier this month the WHO said that Bharat Biotech ldquohas been submitting data to WHO on a rolling basis and submitted additional information at the WHOs request on September 27 The WHO experts are currently reviewing this information and if it addresses all questions raised the WHO assessment will be finalised next weekThe Genevabased WHO said it began rolling data of the vaccine on July 6 Rolling data allows the WHO to start its review right away as information continues to come in to accelerate the overall review processAccording to the WHO submissions for prequalification or listing under the emergency use procedure are confidentialIf a product submitted for assessment is found to meet the criteria for listing the WHO will publish the results widelyDuration of the emergency use listing process depends on the quality of the data submitted by the vaccine manufacturer and on the data meeting the WHOs criteria according to the agencyThe indigenouslydeveloped Bharat Biotechs Covaxin is one of the six vaccines that have received emergency use authorisation from Indias drug regulator Drugs Controller General of India DGCI and is being used in the nationwide antiCOVID19 inoculation programme along with Covishield and Sputnik VBharat Biotech recently said it has submitted all data pertaining to Covaxin to the WHO for the EUL and is awaiting feedback from the global health watchdogCOVAXIN clinical trial data was fully compiled and available in June 2021 All Data submitted for Emergency Use Listing EUL Application to World Health Organization in early July We have responded to any clarifications sought by WHO and are awaiting further feedback Bharat Biotech had tweeted last monthWe are diligently working with the WHO to obtain EUL at the earliest the company had said on TuesdayIndia the worlds largest producer of vaccines overall suspended exports of Covid19 vaccines in April to focus on inoculating its own population following a sudden spike in infectionsLast month Union Health Minister Mansukh Mandaviya announced that India will resume the supplies abroadAccording to Johns Hopkins University the coronavirus has claimed 4897386 lives along with 240559605 confirmed cases across the world so farThis story has been sourced from a third party syndicated feed agencies Midday accepts no responsibility or liability for its dependability trustworthiness reliability and data of the text Midday managementmiddaycom reserves the sole right to alter delete or remove without notice the content in its absolute discretion for any reason whatsoever